

DETECTION OF 11 MULTIDRUG RESISTANCE GENES AMONG THE STRAINS OF *A. BAUMANNII* BY COMPUTATIONAL APPROACH

ABSTRACT:

BACKGROUND: *Acinetobacter baumannii* is typically short, rod shaped gram negative bacterium. The World Health Organisation has declared it as an opportunistic pathogen in humans. Multi drug resistance involves different genetic determinants making the pathogen difficult to treat. So this study is undertaken to characterize the 11 different drug resistant genes from 19 virulent strains of *A. baumannii* using in-silico PCR.

AIM: Detect the 11 multidrug resistance genes among strains of *A. baumannii* by computational approach.

MATERIALS & METHODS: 11 multidrug resistance genes of *A. baumannii* were selected. Forward and reverse primers of the 11 genes as reported from earlier studies were used for in-silico PCR amplification. 19 strains of *A. baumannii* set as default strains on the server were chosen and the amplicon bands were observed.

RESULT: Among the 11 multidrug resistance genes only blaOXA-51like and blaADC were detected among the 19 virulent strains of *A. baumannii*.

CONCLUSION: The findings of the study documents the frequency of blaADC and blaOXA-51 like from the selected strains of *A. baumannii*. However further experimental validation must be done towards the periodical surveillance on the drug resistant strains of *A. baumannii* in hospital settings.

Key words: *A. baumannii*; novel blaOXA; adc; blaOXA; resistance: in-silico

Running title: MDR genes among the strains of *A. baumannii*

INTRODUCTION:

Acinetobacter baumannii is typically short, almost round, rod shaped gram negative bacterium. WHO (World Health Organization) has declared it as an opportunistic pathogen in humans, affecting people with compromised immune systems and is becoming increasingly important as a hospital derived infection (1). *A. baumannii* are multidrug resistant bacteria, which have characteristics such as aerobic, pleomorphic, non-motile and coccobacilli bacteria. *A. baumannii* is classified under the moraxellaceae family, which remains difficult to treat. The prevalence of drug resistant strains are continuously increasing and therefore the treatment options are considerably limited (2). Propensity of multi-drug resistance in *A. baumannii* is a significant reason for its major transformation as a nosocomial pathogen. There are three different types of multidrug resistance properties, each has their own systemic quality. MDR-*A. baumannii*, alludes to strains which display protection from more than at least three antimicrobial drug classes. XDR-*A. baumannii*, alludes to all strains impervious to everything except two medication classes. Pan-drug resistance, alludes to opposition shown by the strains to all medication classes, and a development of culture safe *A. baumannii* was accounted for including the segregates that were impervious to carbapenems, colistin and polymyxins (3). This is due to multiple mechanisms of drug resistance shown by *A. baumannii* via impermeable outer membrane, production of enzymes such as different beta lactamases classes which allows resistance towards carbapenems, porin channel alteration, efflux pumps and genetic materials that leads resistance towards fluoroquinolones (4).

Carbapenems have an ability of hydrolysing the beta lactamases (*carbapenamases*) which belong to molecular class D (OXA enzyme) that have constantly emerged around the globe with high prevalence in East Asia. The class D (OXA carbapenems) of *Acinetobacter* species are divided into several phylogenetic subgroups: blaOXA-23like, blaOXA-51like, blaOXA-141like. In recent findings it has been reported that enzymes belonging to the subgroups blaOXA-51 like are intrinsic to *A. baumannii*, that occurs in most (or) all strains, even though very variably

expressed (5). There were identification of two clones showing carbapenems resistance, these are produced by blaOXA-23like enzymes, they are named as OXA23 clone-1 and OXA23 clone-2. The third group called as SE clone, shows variable carbapenem resistance acquired by insertion sequence (6).

According to Ambler classification, the taken enzyme belongs to class-B metallo-beta lactamase (MBLs) and the multidrug resistance class D OXA type carbapenemases and most of them are mediated by plasmids. MBL's are further divided into several groups such as blaVIM, blaIMP, blaGIM and a recent finding has documented blaNDM in almost many clinical strains. In the MBL's activity the presence of divalent cations are needed as co-factors with the action of one or two zinc ions, for the catalytic ability of chelating as an inhibitory agent. All these mentioned 4 MBL's are having high potential for hydrolyzing all beta-lactam antibiotics except for the specific monobactams such as aztreonam (7), (8).

Most studies have documented *A. baumannii* as MDR strains, and show high variations in both their phenotypes and genotypes as nosocomial pathogens. blaTEM, blaSHV-type and blaCTX-type of genes, are responsible for extended spectrum beta-lactamase production that could be mediated by both plasmids and chromosomes. This plays an important role in exhibiting the resistance against later generations cephalosporins such as cefepime, cefotaxime and ceftazidime (9).

In the same line, sulbactam is a beta lactamase inhibitor, when combined with penicillin it lacks the ability of antimicrobial activity in most bacterial species. It possesses both bacteriostatic and bactericidal effects against *A. baumannii* through several mechanisms. With many studies documenting the drug resistance properties among *A. baumannii*, the present study was undertaken to evaluate the frequency of 11 genetic determinants of resistance genes among the 19 different strains of *A. baumannii* by computational approach.

MATERIALS & METHODS:

Study Setting:

This is an observational in-silico study done in the Department of Microbiology, Saveetha Dental College and Hospital. Institutional research approval for the research was obtained (IHEC/SDC/UG-1895/21/151).

This is an original research study where we have selected 19 strains of *A. baumannii* set as default in the in-silico PCR server (10). **These strains are the default organisms given in the server and their resistance is actually not determined.** The genes of target were blaOXA-23like, blaOXA-51like, blaOXA-141like, blaVIM, blaIMP, blaGIM, blaNDM-1, blaTEM, blaSHV, blaCTX and blaADC. Upon the amplification command, the server produced the amplicon bands for evaluation of the band size. From the amplicon bands, the frequency of the distribution of the drug resistant genes among the vital virulent strains of *A. baumannii* were evaluated Further evolutionary relationships were compared with the phylogenetic analysis as done in earlier reports (11,).

RESULTS:

The investigation on the prevalence of the drug resistant genes from 19 different strains of *A. baumannii* (Table 1) using an in-silico amplification server was promising. The results showed the starting position of the amplification in the chromosome or plasmid and the length of each amplicon. Amplicons obtained in each chromosome or plasmid have been tabulated (Table 2) with target genes, primers used, sequenced of primer (5' to 3'), annealing temperature, estimated size of base pair and the frequency of the target genes among the study strains. Among the 11 multidrug resistant genes, we observed 78.94% positivity of blaOXA-51like and 68.42% for blaADC. All the other 9 genes were not present in the selected 19 different strains of *A. baumannii*. We further assessed the evolutionary pattern of the distributed genes among the strains.

Table 1 List of the selected 19 strains of *A. baumannii* for the study

<i>S.No</i>	<i>A. baumannii strains</i>
1	Acinetobacter baumannii 1656-2 chromosome

2	Acinetobacter baumannii AB0057
3	Acinetobacter baumannii AB307-0294
4	Acinetobacter baumannii ACICU
5	Acinetobacter baumannii ATCC 17978
6	Acinetobacter baumannii AYE
7	Acinetobacter baumannii BJAB07104
8	Acinetobacter baumannii BJAB0715
9	Acinetobacter baumannii BJAB0868
10	Acinetobacter baumannii D1279779
11	Acinetobacter baumannii MDR-TJ
12	Acinetobacter baumannii MDR-ZJ06
13	Acinetobacter baumannii SDF
14	Acinetobacter baumannii TCDC-AB0715
15	Acinetobacter baumannii TYTH-1
16	Acinetobacter baumannii ZW85-1
17	Acinetobacter calcoaceticus PHEA-2
18	Acinetobacter sp. ADP1
19	Acinetobacter sp. DR1

Table 2: PCR conditions and the frequency of the genes among the selected strains of *A.baumannii*

Target	Primer	Sequence 5' to3'	AT (°C)	ES (bp)	Bands	Virulence %
blaOXA-23-like	OXA-23-F	GATCGGATTGGAGAACCAG A	52	501	No bands	Nil
	OXA-23-R	GATCGGATTGGAGAACCAG A				
blaOXA-51-like	OXA-51-F	TAATGCTTTGATCGGCCTTG	52	353	15	78.94%
	OXA-51-R	TGGATTGCACTTCATCTTGG				
blaOXA-143-like	OXA-143-F	TGGCACTTTCAGCAGTTCCT	52	149	No bands	Nil
	OXA-143-R	TAATCTTGAGGGGGCCAACC				
blaVIM	VIMgen-F2	GTTTGGTCGCATATCGCAAC	53	382	No bands	Nil
	VIMgen-R2	AATGCGCAGCACCAGGATA G				
blaIMP	IMPgen-F1	GAATAGAATGGTAACTCTC	53	188	No bands	Nil
	IMPgen-R1	CCAAACCACTAGGTTATC				
blaGIM	GIM-F1	TCAATTAGCTCTTGGGCTGA C	53	72	No bands	Nil
	GIM-R1	CGGAACGACCATTTGAATGG				
blaNDM-1	NDM-Fm	GGTTTGGCGATCTGGTTTTTC	52	621	No bands	Nil
	NDM-Rm	CGGAATGGCTCATCACGATC				
blaTEM	TEM up	ATGATGATTCAACATTTCCG	52	858	No bands	Nil

	TEM low	CCAATGCTTAATCAGTGAGG				
blaSHV	SHV up	TTATCTCCCTGTTAGCCACC	50	795	No bands	Nil
	SHV low	GATTTGCTGATTTTCGCTCGG				
blaCTX-M	CTX-MA	CGCTTTGCGATGTGCAG	55	550	No bands	Nil
	CTX-MB	ACCGCGATATCGTTGGT				
blaADC	ADC1	CCGCGACAGCAGGTGGATA	51	420	13	68.42%
	ADC2	TCGGCTGATTTTCTTGTT				
	125R	TAGACGTAGACGTGGTCA				




Figure 1 Amplification bands showing positive for blaOXA-51 like using in-silico PCR amplification among the strains of *A. baumannii* with an amplicon size of 353bp.




Figure 2 showing Amplification bands showing positive for blaADC using in-silico PCR Amplification among the strains of *A. baumannii* with an amplicon size of 420bp.




Figure 3: Phylogenetic tree construction for blaOXA-51like using in-silico PCR amplification among the strains of *A. baumannii*




Figure 4: Phylogenetic tree construction for blaADC using in-silico PCR amplification among the strains of *A. baumannii*

DISCUSSION:

Higher frequency of blaOXA51 and blaADC, were observed in the present study. In the present study blaOXA-51like and blaADC was observed in 78.94% [Figure 1] and 68.42% [Figure 2] respectively. In a previous study 93% of the strains showed the presence of blaOXA-51like (13). Another study has documented the presence of blaADC in a higher percentage when compared with our study (14). In-silico analysis holds to be a promising computational approach to detect the presence of the target genes (15, 16). Selection of *A. baumannii* was done based on the earlier studies related to the frequency of the resistance among the global strains (17-20).

Computational based approach is also a reliable platform to design novel target against potent pathogens and also to detect natural biocompounds to inhibit the same (21-24). The immunoinformatic approach is also been applied for the detection of virulence factors from *A.baumannii* (25-27). [Table-1].

Also there have been other studies stating that there were no higher frequencies of blaOXA-51like [Figure 3] and blaADC [Figure 4] also they have reported that there was only a low frequency of the genetic determinants. In an earlier study (28) they have reported a higher frequency for metallo-beta lactamases enzymes and no detection of Class D (OXA enzymes) on the strains of *A.baumannii*. In the earlier studies (29), detection of higher frequency of extended spectrum beta lactamase producing strains were observed with low frequency of other resistant genes. In silico identification of resistance genes related to tetracycline pumps (30).

Thus the present findings of the study were in both correlating and in contrast with many other earlier studies (31-33). This suggests, the in-silico PCR amplification is best suited for the preliminary identification of the vital genes. However, further studies with the clinical strains in-vitro can render the actual results on the prevalence and distribution of the virulent and resistant genes among *A. baumannii*. The limitation of this study is that it involved only the set default strains in the tool, thus requiring the same evaluation with the clinical strains. The limitation of the study was that the distribution of the resistant determinants was observed as a computational approach. Thus the future prospects are set to evaluate the same using specific in-vitro and in-vivo study models.

CONCLUSION:

The present study had detected the frequency of two vital genetic determinants of resistance among the 11 genes targeted for the study. blaOXA-51 like and blaADC were highly distributed among the selected 19 strains *A. baumannii*. The *in-silico* PCR tool was efficient in the identification of the genetic determinants at a preliminary level. However, further experimental evaluations must be done using the clinical isolates and to periodically monitor the resistance pattern for epidemiological surveillance of *A.baumannii* associated infections.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

FUNDING SOURCE:

The present study was supported by Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha Dental College and Hospitals, Saveetha University, Chennai and was funded by Azul Clothing company.

References:

1. Girija AS S, Priyadharsini J V, A P. Prevalence of Acb and non-Acb complex in elderly population with urinary tract infection (UTI). *Acta Clin Belg.* 2021 Apr;76(2):106–12.
2. Vijayashree Priyadharsini J, Smiline Girija AS, Paramasivam A. In silico analysis of virulence genes in an emerging dental pathogen *A. baumannii* and related species. *Arch Oral Biol.* 2018 Oct;94:93–8.
3. Smiline Girija AS. CLSI based antibiogram profile and the detection of MDR and XDR strains of *Acinetobacter baumannii* isolated from urine samples. *Med J Islam Repub Iran.* 2019; 17(4):1-9.
4. Smiline Girija AS, Vijayashree Priyadharsini J, Paramasivam A. Plasmid encoded *dfrA-1*, *dfrA-5*, *sul 1* and *sul 2* mediated trimethoprim sulfamethoxazole [TMP-SMX] resistance among *Acinetobacter baumannii* isolated from urine samples of patients with severe UTI. *J Glob Antimicrob Resist.* 2019;17:145–6.
5. Priyadharsini JV, Girija ASS, Paramasivam A. An insight into the emergence of *Acinetobacter baumannii* as an oro-dental pathogen and its drug resistance gene profile--An in silico approach. *Heliyon.* 2018;4(12):e01051.
6. Girija SA, Priyadharsini JV, Paramasivam A. Prevalence of carbapenem-hydrolyzing OXA-type β -lactamases among *Acinetobacter baumannii* in patients with severe urinary tract infection. *Acta Microbiol Immunol Hung.* 2019 Dec 9;67(1):49–55.
7. Smiline Girija AS, Vijayashree Priyadharsini J, Paramasivam A. Prevalence of VIM and GIM producing *Acinetobacter baumannii* from patients with severe UTI. *Acta Microbiol Immunol Hung.* 2018;16:1–12.

8. Safari M, Mozaffari Nejad AS, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). *Saudi J Biol Sci*. 2015 Jul;22(4):424–9.
9. Smiline A, Vijayashree JP, Paramasivam A. Molecular characterization of plasmid-encoded blaTEM, blaSHV and blaCTX-M among extended spectrum β -lactamases [ESBLs] producing *Acinetobacter baumannii*. *Br J Biomed Sci*. 2018 Oct;75(4):200–2.
10. Banaganapalli B, Shaik NA, Rashidi OM, Jamalalail B, Bahattab R, Bokhari HA, et al. In Silico PCR. In: Shaik NA, Hakeem KR, Banaganapalli B, Elango R, editors. *Essentials of Bioinformatics, Volume I: Understanding Bioinformatics: Genes to Proteins*. Cham: Springer International Publishing; 2019. p. 355–71.
11. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol Biol Evol*. 1993 May;10(3):512–26.
12. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. *Mol Biol Evol*. 2018 Jun 1;35(6):1547–9.
13. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol*. 2006 Aug;44(8):2974–6.
14. Lopes BS, Amyes SGB. Role of ISAbal and ISAbal25 in governing the expression of blaADC in clinically relevant *Acinetobacter baumannii* strains resistant to cephalosporins. *J Med Microbiol*. 2012 Aug;61(Pt 8):1103–8.
15. Vijayashree Priyadharsini J. In silico validation of the non- antibiotic drugs acetaminophen and ibuprofen as antibacterial agents against red complex pathogens. *J Periodontol*. 2019;
16. Priyadharsini JV, Vijayashree Priyadharsini J, Smiline Girija AS, Paramasivam A. An insight into the emergence of *Acinetobacter baumannii* as an oro-dental pathogen and its drug resistance gene profile – An in silico approach. Vol. 4, *Heliyon*. 2018. p. e01051. 17.
17. **Smiline Girija AS**, Vijayashree Priyadharsini J, Paramasivam Arumugam. CLSI based antibiogram profile and the detection of MDR and XDR strains of *Acinetobacter baumannii* isolated from urine samples. *Medical Journal of the Islamic Republic of Iran*. **2019**; 33(3); 11-16.
18. **Smiline Girija AS**, Vijayashree Priyadharsini J, Paramasivam Arumugam. Molecular characterization of plasmid encoded blaTEM, blaSHV and blaCTX-M among extended spectrum β -lactamases [ESBL's] producing *Acinetobacter baumannii*. *British Journal of biomedical sciences*. 2018; 16(8): 1-3.
19. Vijayashree Priyadharsini J, **Smiline Girija AS**, Paramasivam Arumugam. In-silico analysis of tetracycline resistance in *Acinetobacter baumannii* and its protein diversity. *Acta Microbiol Hellenica*, 2019: 64(1); 1-9

20. **Smiline Girija AS**, Vijayashree Priyadharsini J, Paramasivam Arumugam. Prevalence of VIM and GIM producing *Acinetobacter baumannii* from patients with severe UTI. *Acta microbiologica et immunologica Hungarica* 2018; 16(8): 1-12.
21. Ushanthika T, Smiline Girija AS, Paramasivam A, Priyadharsini JV. An in silico approach towards identification of virulence factors in red complex pathogens targeted by reserpine. *Nat Prod Res.* 2019 Jul 17;1–6.
22. Ramalingam AK, Selvi SGA, Jayaseelan VP. Targeting prolyl tripeptidyl peptidase from *Porphyromonas gingivalis* with the bioactive compounds from *Rosmarinus officinalis*. *Asian Biomed.* 2020;
23. Kumar SP, Girija ASS, Priyadharsini JV. Targeting NM23-H1-mediated inhibition of tumour metastasis in viral hepatitis with bioactive compounds from *Ganoderma lucidum*: A computational study. *pharmaceutical-sciences.* 2020 Apr 30:1-9.
24. Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with *Murraya koengii* bio-compounds: An in-silico approach. *Acta Virol.* 2020;64(1):93–9.
25. Smiline Girija AS. Delineating the immuno-dominant antigenic vaccine peptides against *gacS* sensor kinase in *Acinetobacter baumannii*: An in-silico investigational approach. *Frontiers in Microbiology.* 2020; 11(9): 1-9.
26. Smiline Girija AS, G. Shoba, J Vijayashree Priyadharsini. Accessing the T-cell and B-cell Immunodominant peptides from *A.baumannii* biofilm associated protein (bap) as vaccine candidates: A computational approach. *International Journal of Peptide Research and therapeutics.* 2020; 4(4):1-9.
27. Barma MD, Muthupandiyani I, Samuel SR, Amaechi BT. Inhibition of *Streptococcus mutans*, antioxidant property and cytotoxicity of novel nano-zinc oxide varnish. *Arch Oral Biol.* 2021 Jun;126:105132.
28. Fallah F, Noori M, Hashemi A, Goudarzi H, Karimi A, Erfanimanesh S, et al. Prevalence of *bla* NDM, *bla* PER, *bla* VEB, *bla* IMP, and *bla* VIM Genes among *Acinetobacter baumannii* Isolated from Two Hospitals of Tehran, Iran. *Scientifica.* 2014 Jul 15;2014:245162.
29. Alyamani EJ, Khiyami MA, Booq RY, Alnafjan BM, Altammami MA, Bahwerth FS. Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of *Acinetobacter baumannii* in Saudi Arabia. *Ann Clin Microbiol Antimicrob.* 2015 Aug 20;14:38.
30. Sivaharini, Smiline Girija AS, Vijayashree Priyadharsini J. Evaluation of the inhibitory effect of caffeic and gallic acid on *tetR* and *tet M* efflux pumps mediating tetracycline resistance in *Streptococcus sp.*, *Journal of King Saud University (Science)*, 2020, 32(1); 904-909.
31. Smiline Girija AS, Vijayashree Priyadharsini J, Paramasivam Arumugam. Prevalence of

VIM and GIM producing *Acinetobacter baumannii* from patients with severe UTI. *Acta microbiologica et immunologica Hungarica* 2018; 16(8): 1-12..

32. Smiline Girija AS, Vijayashree Priyadharsini J, Paramasivam Arumugam. Plasmid encoded tet-A and tet-B mediated tetracycline, doxycycline and minocycline resistance among *Acinetobacter baumannii* isolated from urine samples. *Roum Arch of Microbiol and Immunol*, 2017;76:134-140.
33. Iswarya Jaisankar A, Smiline Girija AS, Gunasekaran S, Vijayashree Priyadharsini J. Molecular characterisation of csgA gene among ESBL strains of *A. baumannii* and targeting with essential oil compounds from *Azadirachta indica*. *Journal of King Saud University - Science*. 2020;32(8):3380–7.

UNDER PEER REVIEW